Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRY INSIGHTS –
4.3.1 MICRO AND MACROECONOMIC FACTORS
4.3.2 PENETRATION AND GROWTH PROSPECT MAPPING
4.3.3 KEY PRICING STRATEGIES
4.3.4 ANALYSIS AND RECOMMENDATION
4.4 INNOVATION TRACKER & STRATEGIC ANALYSIS
4.4.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
4.4.1.1 MERGERS & ACQUISITIONS
4.4.1.2 TECHNOLOGY COLLABORATIONS
4.4.2 NUMBER OF PRODUCTS IN DEVELOPMENT
4.4.3 STAGE OF DEVELOPMENT
4.4.4 TIMELINES & MILESTONES
4.4.5 INNOVATION STRATEGIES & METHODOLOGIES
4.4.6 RISK ASSESSMENT & MITIGATION
4.4.7 FUTURE OUTLOOK
4.5 PIPELINE ANALYSIS – MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET
4.5.1 CLINICAL TRIALS AND PHASE ANALYSIS
4.5.2 DRUG THERAPY PIPELINE
4.5.3 PHASE III CANDIDATES
4.5.4 PHASE II CANDIDATES
4.5.5 PHASE I CANDIDATES
4.5.6 OTHERS (PRE-CLINICAL AND RESEARCH)
4.5.7 CONCLUSION
4.6 EPIDEMIOLOGY–
4.6.1 INCIDENCE OF LYMPHEDEMA (MIDDLE EAST AND AFRICA & BY GENDER)
4.6.2 INCIDENCE OF LYMPHEDEMA BY GENDER
4.6.3 TREATMENT RATE
4.6.4 MORTALITY RATE
4.6.5 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.6.6 PATIENT TREATMENT SUCCESS RATES
4.7 TARIFF
4.7.1 OVERVIEW
4.7.2 TARIFF STRUCTURES
4.7.2.1 Middle East And Africa vs. Regional Tariff Structures
4.7.2.2 United States: Medicare/Medicaid Tariff Policies, CMS Pricing Models
4.7.2.3 European Union: Cross-border Tariff Regulations and Reimbursement Policies
4.7.2.4 Asia-Pacific: Government-imposed Tariffs on Imported Medical Products
4.7.2.5 Emerging Markets: Challenges in Tariff Implementation
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS
4.7.3.1 Import Duties on Prescription Drugs vs. Generics
4.7.3.2 Impact on Drug Affordability and Access
4.7.3.3 Key Trade Agreements Affecting Pharmaceutical Tariffs
4.7.4 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS
4.7.4.1 Cost Burden on Hospitals and Healthcare Facilities
4.7.4.2 Effect on Patient Affordability and Insurance Coverage
4.7.4.3 Tariffs and Their Role in Medical Tourism
4.7.5 TRADE AGREEMENTS AND HEALTHCARE TARIFFS
4.7.5.1 WTO Regulations on Healthcare Tariffs
4.7.5.2 Impact of Trade Wars on the Healthcare Supply Chain
4.7.5.3 Role of Free Trade Agreements (FTAs) in Reducing Tariffs
4.7.6 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY
4.7.7 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR
5 REGULATORY FRAMEWORK–
5.1 NORTH AMERICA
5.2 SOUTH AMERICA
5.3 EUROPE
5.4 ASIA-PACIFIC
5.5 MIDDLE EAST & AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN THE NUMBER OF LYMPHEDEMA CASES GLOBALLY
6.1.2 INCREASE IN THE PREVALENCE OF CANCERS
6.1.3 INCREASING NUMBER OF HEALTHCARE FACILITIES
6.1.4 AVAILABILITY AND ADVANCEMENT OF MULTIPLE THERAPEUTIC OPTIONS
6.2 RESTRAINTS
6.2.1 SIGNIFICANT COST BURDEN ASSOCIATED WITH LYMPHEDEMA MANAGEMENT
6.2.2 LACK OF AWARENESS ABOUT THE DISEASE
6.3 OPPORTUNITIES
6.3.1 EXPANDING OPPORTUNITIES FOR DRUG DEVELOPMENT AND REGULATORY APPROVALS
6.3.2 STRATEGIC COLLABORATIONS AND ALLIANCES AMONG INDUSTRY STAKEHOLDERS
6.4 CHALLENGES
6.4.1 ABSENCE OF A DEFINITIVE CURATIVE TREATMENT
6.4.2 RESTRICTIVE AND INCONSISTENT REIMBURSEMENT POLICIES
7 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 COMPRESSION THERAPY
7.3 SURGERY
7.4 DRUG THERAPY
7.5 LASER THERAPY
7.6 OTHERS
8 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE
8.1 OVERVIEW
8.2 SECONDARY LYMPHEDEMA
8.3 PRIMARY LYMPHEDEMA
9 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA
9.1 OVERVIEW
9.2 LOWER EXTREMITY
9.3 UPPER EXTREMITY
9.4 GENITALIA
10 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 ADULT
10.3 GERIATRIC
10.4 PEDIATRIC
11 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.3 INJECTABLE
11.4 TOPICAL
12 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER
12.1 OVERVIEW
12.2 HOSPITAL
12.3 SPECIALTY CLINICS
12.4 AMBULATORY SURGICAL CENTERS
12.5 OTHERS
13 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 PHARMACY STORES
13.3 DIRECT TENDER
13.4 OTHERS
14 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY REGION
14.1 MIDDLE EAST AND AFRICA
14.1.1 SOUTH AFRICA
14.1.2 SAUDI ARABIA
14.1.3 EGYPT
14.1.4 U.A.E.
14.1.5 ISRAEL
14.1.6 KUWAIT
14.1.7 REST OF MIDDLE EAST AND AFRICA
15 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 TACTILE MEDICAL
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 ESSITY AKTIEBOLAG (PUBL)
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 3M
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENTS
17.4 CARDINAL HEALTH
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 LOHMANN & RAUSCHER GMBH & CO. KG
17.5.1 COMPANY SNAPSHOT
17.5.2 COMPANY SHARE ANALYSIS
17.5.3 PRODUCT PORTFOLIO
17.5.4 RECENT DEVELOPMENT
17.6 AIROS MEDICAL, INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 PRODUCT PORTFOLIO
17.6.3 RECENT DEVELOPMENT
17.7 ARJO
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENTS
17.8 AVET PHARMACEUTICALS INC.
17.8.1 COMPANY SNAPSHOT
17.8.2 PRODUCT PORTFOLIO
17.8.3 RECENT DEVELOPMENT
17.9 BAUERFEIND
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENTS
17.1 BIOCOMPRESSION SYSTEMS
17.10.1 COMPANY SNAPSHOT
17.10.2 PRODUCT PORTFOLIO
17.10.3 RECENT DEVELOPMENT
17.11 CONVATEC INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 PRODUCT PORTFOLIO
17.11.3 RECENT DEVELOPMENT
17.12 ENOVIS CORPORATION
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENTS
17.13 HUNTLEIGH HEALTHCARE LIMITED
17.13.1 COMPANY SNAPSHOT
17.13.2 PRODUCT PORTFOLIO
17.13.3 RECENT DEVELOPMENT
17.14 IMPEDIMED LIMITED
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT/NEWS
17.15 JODAS EXPOIM PVT. LTD.
17.15.1 COMPANY SNAPSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 JUZO
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENT
17.17 KOYA MEDICAL
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 LLC BINNOPHARM GROUP
17.18.1 COMPANY SNAPSHOT
17.18.2 PRODUCT PORTFOLIO
17.18.3 RECENT DEVELOPMENT
17.19 MCKESSON MEDICAL-SURGICAL INC.
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENT
17.2 MEDI GMBH & CO. KG
17.20.1 COMPANY SNAPSHOT
17.20.2 PRODUCT PORTFOLIO
17.20.3 RECENT DEVELOPMENT
17.21 MEDTRONIC
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENTS
17.22 MEGO AFEK LTD
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 PAUL HARTMANN AG
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 PERFORMANCE HEALTH
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENTS
17.25 PURETECH HEALTH INC
17.25.1 COMPANY SNAPSHOT
17.25.2 PIPELINE PORTFOLIO
17.25.3 RECENT DEVELOPMENT
17.26 SANYLEG SRL A SOCIO UNICO
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
17.27 SIGVARIS GROUP
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENTS
17.28 SMITH+NEPHEW
17.28.1 COMPANY SNAPSHOT
17.28.2 REVENUE ANALYSIS
17.28.3 PRODUCT PORTFOLIO
17.28.4 RECENT DEVELOPMENT
17.29 THERMOTEK
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENT
17.3 THUASNE
17.30.1 COMPANY SNAPSHOT
17.30.2 PRODUCT PORTFOLIO
17.30.3 RECENT DEVELOPMENT
17.31 VIATRIS INC.
17.31.1 COMPANY SNAPSHOT
17.31.2 REVENUE ANALYSIS
17.31.3 PRODUCT PORTFOLIO
17.31.4 RECENT DEVELOPMENT
17.32 WHITE SWAN PHARMACEUTICAL
17.32.1 COMPANY SNAPSHOT
17.32.2 PRODUCT PORTFOLIO
17.32.3 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 PRODUCTS AND THEIR STAGES IN DEVELOPMENT.
TABLE 2 PHASE-WISE DISTRIBUTION: CLINICAL TRIALS
TABLE 3 PHASE 2 CANDIDATES
TABLE 4 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 6 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION 2018-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA LASER THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA SECONDARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA LOWER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA UPPER EXTREMITY IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA GENITALIA IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA ADULT IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA GERIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA PEDIATRIC IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA ORAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA INJECTABLE IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA TOPICAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA HOSPITAL IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA PHARMACY STORES IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA DIRECT TENDER IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN LYMPHEDEMA TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 44 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 45 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 59 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 60 SOUTH AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 61 SOUTH AFRICA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 62 SOUTH AFRICA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 63 SOUTH AFRICA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 SOUTH AFRICA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 SOUTH AFRICA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 68 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 69 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 70 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 71 SOUTH AFRICA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 72 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 74 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 75 SAUDI ARABIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 76 SAUDI ARABIA COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 77 SAUDI ARABIA COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 78 SAUDI ARABIA SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 SAUDI ARABIA DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 80 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 SAUDI ARABIA PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 83 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 84 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 85 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 86 SAUDI ARABIA LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 87 EGYPT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 EGYPT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 89 EGYPT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 90 EGYPT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 91 EGYPT COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 92 EGYPT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 93 EGYPT SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 EGYPT DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 EGYPT LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 EGYPT PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 EGYPT LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 98 EGYPT LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 99 EGYPT LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 100 EGYPT LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 101 EGYPT LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 102 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 103 U.A.E LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 104 U.A.E LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 105 U.A.E. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 106 U.A.E. COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 107 U.A.E. COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 108 U.A.E. SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 U.A.E. DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 U.A.E. PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 113 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 114 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 115 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 116 U.A.E. LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 117 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 118 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 119 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 120 ISRAEL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 121 ISRAEL COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 122 ISRAEL COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 123 ISRAEL SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 124 ISRAEL DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 ISRAEL PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 128 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 129 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 130 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 131 ISRAEL LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 132 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 134 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 135 KUWAIT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 136 KUWAIT COMPRESSION GARMENTS IN LYMPHEDEMA TREATMENT MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)
TABLE 137 KUWAIT COMPRESSION THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TECHNIQUE, 2018-2032 (USD THOUSAND)
TABLE 138 KUWAIT SURGERY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 KUWAIT DRUG THERAPY IN LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 KUWAIT PRIMARY LYMPHEDEMA IN LYMPHEDEMA TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY AFFECTED AREA, 2018-2032 (USD THOUSAND)
TABLE 143 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 144 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 145 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 146 KUWAIT LYMPHEDEMA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 147 REST OF MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 REST OF MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 149 REST OF MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (ASP IN USD/UNITS)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EXECUTIVE SUMMARY
FIGURE 11 FIVE SEGMENTS COMPRISE THE MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET, BY TREATMENT TYPE (2024)
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: SEGMENTATION
FIGURE 14 INCREASE IN THE PREVALENCE OF CANCERS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 THE COMPRESSION THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET IN 2025 AND 2032
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF INDONESIA ZEOLITE MARKET
FIGURE 17 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 18 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 20 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 21 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2024
FIGURE 22 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 23 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 24 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2024
FIGURE 26 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, 2025-2032 (USD THOUSAND)
FIGURE 27 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, CAGR (2025-2032)
FIGURE 28 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AFFECTED AREA, LIFELINE CURVE
FIGURE 29 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2024
FIGURE 30 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)
FIGURE 31 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 32 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 33 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024
FIGURE 34 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2025-2032 (USD THOUSAND)
FIGURE 35 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2025-2032)
FIGURE 36 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 37 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2024
FIGURE 38 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 39 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 40 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 41 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 42 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 43 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 44 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 46 MIDDLE EAST AND AFRICA LYMPHEDEMA TREATMENT MARKET: COMPANY SHARE 2024 (%)
